TY - JOUR
T1 - Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement
AU - Yoon, Sung Han
AU - Bleiziffer, Sabine
AU - Latib, Azeem
AU - Eschenbach, Lena
AU - Ancona, Marco
AU - Vincent, Flavien
AU - Kim, Won Keun
AU - Unbehaum, Axel
AU - Asami, Masahiko
AU - Dhoble, Abhijeet
AU - Silaschi, Miriam
AU - Frangieh, Antonio H.
AU - Veulemans, Verena
AU - Tang, Gilbert H.L.
AU - Kuwata, Shingo
AU - Rampat, Rajiv
AU - Schmidt, Tobias
AU - Patel, Amisha J.
AU - Nicz, Pedro Felipe Gomez
AU - Nombela-Franco, Luis
AU - Kini, Annapoorna
AU - Kitamura, Mitsunobu
AU - Sharma, Rahul
AU - Chakravarty, Tarun
AU - Hildick-Smith, David
AU - Arnold, Martin
AU - de Brito, Fabio Sandoli
AU - Jensen, Christoph
AU - Jung, Christian
AU - Jilaihawi, Hasan
AU - Smalling, Richard W.
AU - Maisano, Francesco
AU - Kasel, Albert Markus
AU - Treede, Hendrik
AU - Kempfert, Joerg
AU - Pilgrim, Thomas
AU - Kar, Saibal
AU - Bapat, Vinayak
AU - Whisenant, Brian K.
AU - Van Belle, Eric
AU - Delgado, Victoria
AU - Modine, Thomas
AU - Bax, Jeroen J.
AU - Makkar, Raj R.
N1 - Funding Information:
The Department of Cardiology of the Leiden University Medical Center received unrestricted research grants from Edwards Lifesciences, Biotronik, Medtronic, and Boston Scientific. Dr. Bleiziffer has served as a consultant to Medtronic; has served as a proctor for Medtronic and JenaValve; and has received travel compensation from Edwards Lifesciences, Medtronic, and Johnson & Johnson. Dr. Latib has served on an advisory board for Medtronic; and has served as a consultant for Direct Flow Medical. Dr. Kim has served as a proctor for Symmetis and St. Jude Medical. Dr. Dhoble has served as a proctor for Edwards Lifesciences; and has served as a consultant for St. Jude Medical. Dr. Tang has served as a proctor for Edwards Lifesciences. Dr. Smith has served as a proctor for Medtronic and Boston Scientific. Dr. Arnold has received travel compensation from Edwards Lifesciences; has served as a proctor for Edwards Lifesciences; has served as a proctor and consultant for St. Jude Medical; and has received speaking honoraria from JenaValve. Dr. Jilaihawi has served as a consultant for Edwards Lifesciences, St. Jude Medical, and Venus Medtech. Dr. Smalling has received consulting fees and research support from St. Jude and Edwards Lifesciences. Dr. Maisano has served as a consultant for Edwards Lifesciences, Medtronic, St. Jude Medical, Abbott Vascular, and Veltech; and has received royalties from Edwards Lifesciences. Dr. Kasel has served as a consultant for Edwards Lifesciences and received research support from Edwards Lifesciences. Dr. Treede has served as a proctor and consultant for Edwards Lifesciences. Dr. Pilgrim has received speaking fees from Biotronik and Medtronic; and has received travel honoraria from Biotronik and Edwards Lifesciences. Dr. Kempfert has served as a proctor for Edwards Lifesciences, Abbott Vascular, Medtronic, and Biotronik. Dr. Kar has served as a consultant for Abbott Vascular and Boston Scientific. Dr. Bapat has served as a consultant for Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, and 4Tech. Dr. Whisenant has served as a consultant for Edwards Lifesciences and Boston Scientific. Dr. Delgado has received speaking fees from Abbott Vascular. Dr. Modine has served as a consultant for Boston Scientific. Dr. Makkar has received grants from Edwards Lifesciences; and has received personal fees from St. Jude Medical and Medtronic. All other authors have reported that they have no relationship relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2019 American College of Cardiology Foundation
PY - 2019/1/28
Y1 - 2019/1/28
N2 - Objectives: The aim of this study was to evaluate the predictors of left ventricular outflow tract (LVOT) obstruction after transcatheter mitral valve replacement (TMVR). Background: LVOT obstruction is a major concern with TMVR, but limited data exist regarding its predictors and impact on outcomes. Methods: Patients with pre-procedural multidetector row computed tomography (MDCT) undergoing TMVR for failed mitral bioprosthetic valves (valve-in-valve), annuloplasty rings (valve-in-ring), and mitral annular calcification (valve-in-MAC) were included in this study. Echocardiographic and procedural characteristics were recorded, and comprehensive assessment with MDCT was performed to identify the predictors of LVOT obstruction (defined as an increment of mean LVOT gradient ≥10 mm Hg from baseline). The new LVOT (neo-LVOT) area left after TMVR was estimated by embedding a virtual valve into the mitral annulus on MDCT, simulating the procedure. Results: Among 194 patients with pre-procedural MDCT undergoing TMVR (valve-in-valve, 107 patients; valve-in-ring, 50 patients; valve-in-MAC, 37 patients), LVOT obstruction was observed in 26 patients (13.4%), with a higher rate after valve-in-MAC than valve-in-ring and valve-in-valve (54.1% vs. 8.0% vs. 1.9%; p < 0.001). Patients with LVOT obstruction had significantly higher procedural mortality compared with those without LVOT obstruction (34.6% vs. 2.4%; p < 0.001). Receiver-operating characteristic curve analysis showed that an estimated neo-LVOT area ≤1.7 cm2 predicted LVOT obstruction with sensitivity of 96.2% and specificity of 92.3%. Conclusions: LVOT obstruction after TMVR was associated with higher procedural mortality. A small estimated neo-LVOT area was significantly associated with LVOT obstruction after TMVR and may help identify patients at high risk for LVOT obstruction.
AB - Objectives: The aim of this study was to evaluate the predictors of left ventricular outflow tract (LVOT) obstruction after transcatheter mitral valve replacement (TMVR). Background: LVOT obstruction is a major concern with TMVR, but limited data exist regarding its predictors and impact on outcomes. Methods: Patients with pre-procedural multidetector row computed tomography (MDCT) undergoing TMVR for failed mitral bioprosthetic valves (valve-in-valve), annuloplasty rings (valve-in-ring), and mitral annular calcification (valve-in-MAC) were included in this study. Echocardiographic and procedural characteristics were recorded, and comprehensive assessment with MDCT was performed to identify the predictors of LVOT obstruction (defined as an increment of mean LVOT gradient ≥10 mm Hg from baseline). The new LVOT (neo-LVOT) area left after TMVR was estimated by embedding a virtual valve into the mitral annulus on MDCT, simulating the procedure. Results: Among 194 patients with pre-procedural MDCT undergoing TMVR (valve-in-valve, 107 patients; valve-in-ring, 50 patients; valve-in-MAC, 37 patients), LVOT obstruction was observed in 26 patients (13.4%), with a higher rate after valve-in-MAC than valve-in-ring and valve-in-valve (54.1% vs. 8.0% vs. 1.9%; p < 0.001). Patients with LVOT obstruction had significantly higher procedural mortality compared with those without LVOT obstruction (34.6% vs. 2.4%; p < 0.001). Receiver-operating characteristic curve analysis showed that an estimated neo-LVOT area ≤1.7 cm2 predicted LVOT obstruction with sensitivity of 96.2% and specificity of 92.3%. Conclusions: LVOT obstruction after TMVR was associated with higher procedural mortality. A small estimated neo-LVOT area was significantly associated with LVOT obstruction after TMVR and may help identify patients at high risk for LVOT obstruction.
KW - annuloplasty ring
KW - degenerated bioprosthesis
KW - left ventricular outflow tract obstruction
KW - mitral annular calcification
KW - mitral valve
KW - transcatheter valve implantation
UR - http://www.scopus.com/inward/record.url?scp=85059845613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059845613&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2018.12.001
DO - 10.1016/j.jcin.2018.12.001
M3 - Article
C2 - 30678797
AN - SCOPUS:85059845613
SN - 1936-8798
VL - 12
SP - 182
EP - 193
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 2
ER -